ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $18.66, but opened at $18.25. ACADIA ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...

As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

Guggenheim analyst Yatin Suneja downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a $20 price target Don't Miss Our New Year's ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 ...

The primary catalyst for Acadia Pharmaceuticals’ recent stock movement is its inclusion in the S&P SmallCap 600 Index. Starting January 3, 2025, Acadia will replace Independent Bank Group Inc. (NASDAQ ...

Shares of Acadia Pharmaceuticals rose after the company said it was set to join the S&P SmallCap 600 index. The biopharmaceutical company's stock jumped 12% to $18.73 in morning trading Tuesday, ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...